Operator

Good morning, and thank you for standing by. [Operator Instructions] Please be advised that today's conference call is being recorded.

I would now like to turn the conference over to Michael Polyviou. Please go ahead.

Michael Polyviou

Thank you, operator. And welcome to IceCure Medical's conference call to review the financial results as of and for the 3 months ended March 31, 2026 and provide an update on recent operational highlights. You may refer to the earnings press release that we issued earlier this morning. Participating on today's call are IceCure Medical's CEO, Eyal Shamir, the company's VP Sales North America; Shad Good; and our guest, Dr. Richard Fine, a key opinion leader in the treatment of breast cancer, a breast surgeon and ICE3 investigator who has published and presented ICE3 data and is active in hands-on trainings and symposia for cryoablation in the treatment of early-stage breast cancer.

Before we begin, I will now take a moment to read a statement about forward-looking statements. This call and the question-and-answer session that follows it contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks and estimates and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements in this presentation when we discuss IceCure's accelerating commercial momentum and growing engagement for